Targeting the microenvironment: a new treatment paradigm for chronic
lymphocytic leukaemia
Asher Chanan-Khan Roswell Park Cancer
Institute, Buffalo, NY, USA
Chronic lymphocytic leukaemia (CLL) is one of the most common leukaemias to affect adults, comprising about 30% of all leukaemia cases and 20% of leukaemia-related deaths each year.1 The incidence is 3/100,000 per year in the western hemisphere,2 and, in the USA alone, an estimated 10,000 new cases are expected in 2006 and a further 4,660 men and women are expected to die from the disease.
[>Read full article in PDF]